PL371327A1 - Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) - Google Patents

Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Info

Publication number: PL371327A1
Authority: PL; Poland
Prior art keywords: ifn; interleukin; interrupting; immune reactions; reactions induced
Prior art date: 2002-02-15

Application number

PL03371327A

Other languages

English (en)

Polish (pl)

Inventor

Thorsten Blume

Wolf-Dietrich Döcke

Wolfgang Halfbrodt

Joachim Kuhnke

Ursula Mönning

Bernd Elger

Herbert Schneider

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-15

Filing date

2003-01-17

Publication date

2005-06-13

2003-01-17 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2005-06-13 Publication of PL371327A1 publication Critical patent/PL371327A1/xx

Links

102000013462 Interleukin-12 Human genes 0.000 title 1
108010065805 Interleukin-12 Proteins 0.000 title 1
230000008105 immune reaction Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229940117681 interleukin-12 Drugs 0.000 title 1
210000000274 microglia Anatomy 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL03371327A 2002-02-15 2003-01-17 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) PL371327A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10207843A DE10207843A1 (de)	2002-02-15	2002-02-15	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Publications (1)

Publication Number	Publication Date
PL371327A1 true PL371327A1 (en)	2005-06-13

Family

ID=27674912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03371327A PL371327A1 (en)	2002-02-15	2003-01-17	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Country Status (21)

Country	Link
EP (1)	EP1474138A1 (sr)
JP (1)	JP2005522447A (sr)
KR (1)	KR20040084909A (sr)
CN (1)	CN1756546A (sr)
AR (1)	AR039556A1 (sr)
AU (1)	AU2003245523A1 (sr)
BR (1)	BR0307706A (sr)
CA (1)	CA2475770A1 (sr)
DE (1)	DE10207843A1 (sr)
EC (1)	ECSP045297A (sr)
MX (1)	MXPA04007943A (sr)
NO (1)	NO20043840L (sr)
PE (1)	PE20030906A1 (sr)
PL (1)	PL371327A1 (sr)
RS (1)	RS71304A (sr)
RU (1)	RU2004127677A (sr)
TW (1)	TW200306823A (sr)
UA (1)	UA81111C2 (sr)
UY (1)	UY27662A1 (sr)
WO (1)	WO2003068225A1 (sr)
ZA (1)	ZA200407382B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10207844A1 (de) *	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US7820637B2 (en) *	2005-03-17	2010-10-26	Proyecto De Biomedicina Cima, S.L.	Use of 5′-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
CA2874303C (en) *	2012-06-11	2020-10-13	Ucb Biopharma Sprl	Tnf -alpha modulating benz imidazoles
WO2016130501A1 (en)	2015-02-09	2016-08-18	Incyte Corporation	Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI744256B (zh)	2015-11-06	2021-11-01	美商英塞特公司	作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
EP3390367B1 (en) *	2015-12-15	2020-09-09	The Board of Trustees of the Leland Stanford Junior University	Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
TW201734003A (zh)	2016-01-05	2017-10-01	英塞特公司	作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es)	2016-06-24	2018-10-03	Incyte Corp	COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AU2018350980C1 (en)	2017-10-18	2024-12-12	Incyte Corporation	Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
CR20250050A (es)	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
PT3860998T (pt)	2018-10-05	2024-04-02	Annapurna Bio Inc	Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
CN112341451B (zh) *	2019-08-09	2022-06-17	成都先导药物开发股份有限公司	一种免疫调节剂
CN112341450B (zh) *	2019-08-09	2022-05-17	成都先导药物开发股份有限公司	一种免疫调节剂
CA3165339A1 (en) *	2019-12-19	2021-06-24	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Cd206 modulators their use and methods for preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4330959A1 (de) *	1993-09-09	1995-03-16	Schering Ag	Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
NZ519326A (en) *	2000-01-14	2005-02-25	Schering Ag	1,2-diarylbenzimidazoles for treating diseases that are associated with a microglia activation
DE10134775A1 (de) *	2001-07-06	2003-01-30	Schering Ag	1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) *	2001-07-09	2003-02-06	Schering Ag	1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

2002
- 2002-02-15 DE DE10207843A patent/DE10207843A1/de not_active Ceased
2003
- 2003-01-17 RS YU71304A patent/RS71304A/sr unknown
- 2003-01-17 PL PL03371327A patent/PL371327A1/xx not_active Application Discontinuation
- 2003-01-17 UA UA20040907401A patent/UA81111C2/uk unknown
- 2003-01-17 JP JP2003567407A patent/JP2005522447A/ja active Pending
- 2003-01-17 RU RU2004127677/15A patent/RU2004127677A/ru unknown
- 2003-01-17 EP EP03739380A patent/EP1474138A1/de not_active Withdrawn
- 2003-01-17 CN CNA038039923A patent/CN1756546A/zh active Pending
- 2003-01-17 MX MXPA04007943A patent/MXPA04007943A/es unknown
- 2003-01-17 CA CA002475770A patent/CA2475770A1/en not_active Abandoned
- 2003-01-17 KR KR10-2004-7012557A patent/KR20040084909A/ko not_active Ceased
- 2003-01-17 BR BR0307706-3A patent/BR0307706A/pt not_active IP Right Cessation
- 2003-01-17 WO PCT/EP2003/000467 patent/WO2003068225A1/de not_active Ceased
- 2003-01-17 AU AU2003245523A patent/AU2003245523A1/en not_active Abandoned
- 2003-02-03 PE PE2003000119A patent/PE20030906A1/es not_active Application Discontinuation
- 2003-02-11 UY UY27662A patent/UY27662A1/es not_active Application Discontinuation
- 2003-02-12 AR ARP030100436A patent/AR039556A1/es unknown
- 2003-02-14 TW TW092103072A patent/TW200306823A/zh unknown
2004
- 2004-09-14 EC EC2004005297A patent/ECSP045297A/es unknown
- 2004-09-14 ZA ZA200407382A patent/ZA200407382B/en unknown
- 2004-09-14 NO NO20043840A patent/NO20043840L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200306823A (en)	2003-12-01
JP2005522447A (ja)	2005-07-28
BR0307706A (pt)	2005-01-11
PE20030906A1 (es)	2004-01-17
MXPA04007943A (es)	2004-11-26
ZA200407382B (en)	2005-09-14
UA81111C2 (en)	2007-12-10
WO2003068225A1 (de)	2003-08-21
KR20040084909A (ko)	2004-10-06
AU2003245523A1 (en)	2003-09-04
CN1756546A (zh)	2006-04-05
RS71304A (sr)	2006-10-27
NO20043840L (no)	2004-11-12
AR039556A1 (es)	2005-02-23
CA2475770A1 (en)	2003-08-21
DE10207843A1 (de)	2003-09-04
UY27662A1 (es)	2003-09-30
RU2004127677A (ru)	2005-06-10
EP1474138A1 (de)	2004-11-10
ECSP045297A (es)	2004-10-26

Legal Events

Date	Code	Title	Description
2011-04-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
GB0209511D0 (en)	2002-06-05	Computer system and method
AU2002234755A1 (en)	2002-09-12	Interferon-alpha induced gene
IL136454A0 (en)	2001-06-14	Compositions and methods for inducing gene expression
TW524094U (en)	2003-03-11	Retaining and recovering apparatus for spines
HUP0500041A3 (en)	2008-09-29	Oligonicleotide having 2'-o-(2-methoxyl)ethyl modifications and therapy using thereof
GB2389386B (en)	2005-11-23	Fall protection system and apparatus
EP1372631A4 (en)	2005-07-27	METHOD AND FORMULA FOR ANTITUMOR AND ANTIMETASTATIC EFFECT
AU2002325433A8 (en)	2004-02-23	Method for correcting immune responses and medicinal agent
EP1542609B8 (en)	2013-02-20	Pharmaceutical compositions comprising Interferon beta for use in treating melanoma
HUP0303645A3 (en)	2005-12-28	Interferon gamma polypeptide variants
ZA200600025B (en)	2007-03-28	Methods and compositions for interferon therapy
PL359562A1 (en)	2004-08-23	Interferon for treatment of multiple sclerosis
AU2002366809A8 (en)	2003-07-09	Syn3 compositions and methods
AU2002363522A8 (en)	2003-05-19	System and method for improved computer drug design
AU2003225710A8 (en)	2003-09-22	Composition and method for enhancing immune response
IL158440A0 (en)	2004-05-12	Vaccines including as an adjuvant type 1 ifn and processes related thereto
EP1406720A4 (en)	2005-06-22	BUFFERS FOR ELECTROPHORESIS AND USE THEREOF
IL153176A (en)	2012-10-31	Phenylpiperazines and pharmaceutical compositions comprising them
AU2003275069A8 (en)	2004-04-08	Compositions and methods for preventing infection
GB0030184D0 (en)	2001-01-24	Interferon alpha induced gene
GB0112453D0 (en)	2001-07-11	Interferon-alpha induced gene
AU2003297297A8 (en)	2004-06-18	Elf3 gene compositions and methods
GB0218473D0 (en)	2002-09-18	Interferon-alpha induced gene
GB0200619D0 (en)	2002-02-27	Interferon-alpha induced gene
GB0104706D0 (en)	2001-04-11	Interferon - alpha induced gene